V
31.20
3.16 (11.27%)
| Previous Close | 28.04 |
| Open | 27.97 |
| Volume | 4,046,888 |
| Avg. Volume (3M) | 1,901,488 |
| Market Cap | 4,017,374,464 |
| Price / Book | 1.09 |
| 52 Weeks Range | |
| Earnings Date | 6 May 2025 - 12 May 2025 |
| Diluted EPS (TTM) | -3.80 |
| Total Debt/Equity (MRQ) | 2.15% |
| Current Ratio (MRQ) | 12.76 |
| Operating Cash Flow (TTM) | -452.63 M |
| Levered Free Cash Flow (TTM) | -403.44 M |
| Return on Assets (TTM) | -14.47% |
| Return on Equity (TTM) | -20.41% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Vaxcyte, Inc. | Bearish | Bullish |
AIStockmoo Score
2.0
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 5.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Average | 2.00 |
|
Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-24, VAX-A1, and VAX-PG. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
| % Held by Insiders | 0.50% |
| % Held by Institutions | 111.76% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 160.00 (Guggenheim, 412.82%) | Buy |
| Median | 118.50 (279.81%) | |
| Low | 90.00 (Needham, 188.46%) | Buy |
| Average | 121.75 (290.22%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 41.98 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Needham | 08 Apr 2025 | 90.00 (188.46%) | Buy | 30.20 |
| 01 Apr 2025 | 90.00 (188.46%) | Buy | 32.23 | |
| B of A Securities | 01 Apr 2025 | 137.00 (339.10%) | Buy | 32.23 |
| Goldman Sachs | 01 Apr 2025 | 100.00 (220.51%) | Buy | 32.23 |
| Guggenheim | 12 Mar 2025 | 160.00 (412.82%) | Buy | 73.24 |
| 26 Feb 2025 | 160.00 (412.82%) | Buy | 78.65 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| GUGGENHIME ANDREW | - | - | 0 | 0 |
| LUKATCH HEATH | - | - | 0 | 0 |
| PICKERING GRANT | - | - | 0 | 0 |
| Aggregate Net Quantity | 0 | |||
| Aggregate Net Value ($) | 0 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| LUKATCH HEATH | Director | 08 Apr 2025 | Option execute | 7,000 | - | - |
| GUGGENHIME ANDREW | Officer | 07 Apr 2025 | Option execute | 4,777 | - | - |
| PICKERING GRANT | Officer | 04 Apr 2025 | Option execute | 20,533 | - | - |
| Date | Type | Details |
|---|---|---|
| 31 Mar 2025 | Announcement | Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study |
| 30 Mar 2025 | Announcement | Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study |
| 25 Feb 2025 | Announcement | Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update |
| 12 Feb 2025 | Announcement | Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025 |
| 05 Feb 2025 | Announcement | Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants |
| 30 Jan 2025 | Announcement | Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |